Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Schedules,Therapeutic_group
"ROCHE PRODUCTS (NEW ZEALAND) LIMITED, Clinician",Atezolizumab and bevacizumab,"Hepatocellular carcinoma, unresectable, 1st line",Atezolizumab and bevacizumab (Tecentriq),Hospital,Oncology Agents and Immunosuppressants
